Wealth Enhancement Advisory Services LLC Has $62.43 Million Holdings in Cencora, Inc. (NYSE:COR)

Wealth Enhancement Advisory Services LLC boosted its holdings in Cencora, Inc. (NYSE:COR) by 0.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 277,366 shares of the company’s stock after acquiring an additional 289 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Cencora were worth $62,429,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Concord Wealth Partners bought a new stake in Cencora in the 3rd quarter valued at $30,000. SYSTM Wealth Solutions LLC bought a new position in Cencora during the 2nd quarter worth $36,000. Ashton Thomas Securities LLC bought a new position in Cencora during the 3rd quarter worth $41,000. Fairscale Capital LLC bought a new position in Cencora during the 2nd quarter worth $54,000. Finally, Modus Advisors LLC bought a new position in Cencora during the 4th quarter worth $54,000. Institutional investors own 97.52% of the company’s stock.

Insider Activity at Cencora

In other news, Chairman Steven H. Collis sold 50,000 shares of Cencora stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the sale, the chairman now directly owns 326,557 shares of the company’s stock, valued at approximately $79,670,111.29. This trade represents a 13.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. The trade was a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 94,696 shares of company stock valued at $22,862,734 over the last ninety days. 15.80% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

COR has been the topic of several recent research reports. StockNews.com cut Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Evercore ISI raised their price target on Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Wells Fargo & Company decreased their price target on Cencora from $249.00 to $237.00 and set an “equal weight” rating on the stock in a research report on Friday, December 13th. Mizuho initiated coverage on Cencora in a research report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price target on the stock. Finally, Leerink Partners decreased their price target on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research report on Monday, October 7th. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $275.60.

Cencora Stock Performance

NYSE:COR opened at $236.36 on Friday. The stock’s 50-day simple moving average is $237.73 and its 200 day simple moving average is $233.56. The firm has a market capitalization of $45.68 billion, a PE ratio of 31.47, a price-to-earnings-growth ratio of 1.54 and a beta of 0.49. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $253.27.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were paid a $0.55 dividend. The ex-dividend date was Friday, November 15th. This is a positive change from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a yield of 0.93%. Cencora’s dividend payout ratio (DPR) is 29.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.